Merck to phase out osteoporosis specialty team

Share this article:

Merck plans to eliminate its osteoporosis specialty team at the end of the year, ahead of the February 2008 patent expiration of its bone density blockbuster Fosamax.

A total of 250 positions from the osteoporosis team, including some sales jobs, will be impacted, according to Merck spokeswoman Amy Rose.

“We informed this group of individuals well in advance so that we could work with them to find other opportunities within Merck that fit their skills and interest,” Rose told MM&M.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions